C9ORF72 repeat – A genetic repeat expansion in C9ORF72 helps explain why ALS and frontotemporal dementia can appear along a shared disease spectrum—reshaping diagnosis and spurring new therapies.
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) can look like opposites at the bedside—one attacks personality and language, while the other often starts with weakness and trouble swallowing.
Yet geneticists have spent years chasing a single question: could these seemingly separate neurodegenerative diseases share a deeper root?. Work led by researchers including Rosa Rademakers and Bryan Traynor has increasingly pointed to one answer—an unusual expansion in a gene known as C9ORF72 that shows up across families affected by both conditions.
When Traynor and Rademakers and their colleagues reported their findings. the idea landed with force because it reframed the way clinicians think about “syndromes.” For decades. ALS and FTD were tracked in different clinical lanes. treated as distinct entities with different symptom trajectories.. But the genetic connection suggests a spectrum—two clinical endpoints that can be driven by overlapping biological mechanisms.
To get there. the researchers had to solve a problem that classical gene-hunting methods struggle with: a specific kind of DNA change called a repeat expansion.. Most genetic variants differ by swapping one letter in the genetic code for another.. In contrast. a repeat expansion involves a snippet of DNA that gets copied over and over again—sometimes far beyond the normal range.. In the case of C9ORF72. the repeated sequence is the six-letter motif GGGGCC. and in affected individuals it can be present in hundreds or even thousands of copies.
The search began long before the repeat expansion was recognized as the key.. The teams narrowed attention to a region on chromosome 9 where multiple families shared a stretch of DNA.. Early attempts to pinpoint the culprit with standard approaches didn’t show a clear single-letter mutation.. Then the focus shifted—after the researchers began considering that the answer might not be a simple swap but a structural change invisible to some early analyses.. Developing or adapting methods capable of detecting repeat expansions became the technical turning point that finally exposed C9ORF72 as the shared genetic driver.
Importantly, the repeat expansion doesn’t just create one problem.. It appears to do two broad things that can both poison cells and disrupt normal biology.. First. the repeated DNA can generate toxic forms of RNA and small toxic proteins. even though the repeat sits in a noncoding region that isn’t supposed to directly serve as a template for standard proteins.. Second. its location near the C9ORF72 gene can interfere with normal production—meaning cells may lose around half of the typical protein output.
That matters because C9ORF72 is not a bystander.. The gene’s protein is involved in cellular “clearance” functions and in the immune environment inside the brain.. Losing normal function. at the same time as gaining toxic molecular byproducts. creates a dual assault—precisely the kind of complexity that can help explain why the same genetic change might lead to different clinical pictures in different people.
Still. the chain from C9ORF72 repeats to the hallmark protein behavior seen in ALS and FTD is not fully mapped.. A key player is TDP-43. a protein that accumulates in both the spinal cords of ALS patients and the brains of people with FTD.. Researchers now believe TDP-43 is central to how neurons fail and die. but exactly how toxic repeat products and the loss of normal C9ORF72 function converge on TDP-43 remains an open question—one that. even after many years. is still being worked through.
For patients and clinicians. the most immediate impact of the genetic breakthrough has been behavioral: it encouraged ALS teams to look harder for signs that typically belong to FTD.. Traynor describes a shift in how ALS patients are examined, with more careful attention to cognitive and behavioral changes.. In practice. those subtle changes can be missed when ALS patients are seen only through a neuromuscular lens. or when they’re evaluated in settings that don’t routinely probe for the kinds of speech and decision-making alterations that point toward FTD.
The crossover has also helped researchers plan better studies.. Once you know a specific gene mutation can carry risk. the earliest stages of disease become something you can investigate before symptoms appear.. Genetic testing can enable families to identify carriers. and researchers can then follow people across time to detect early warning signs—an approach that could. in theory. help separate cause from consequence and reveal windows when intervention might work.
That’s where therapies enter the picture, and the C9ORF72 story offers both hope and a cautionary lesson.. Companies have tested antisense oligonucleotide (ASO) therapies intended to interfere with toxic molecules.. But results from completed trials have not shown success so far. and researchers point to a central challenge: some approaches may not have restored the normal C9ORF72 protein function that appears to be lost because of the repeat expansion.
Misryoum readers should also note the bigger clinical implication: treatments might need to target more than one mechanism at once.. If disease is driven both by toxic repeat-derived products and by the loss of a protective protein function. then therapies that only silence one part may fall short.. The research community is already preparing for renewed trial strategies built on that mechanistic understanding.
Another unanswered question sits at the heart of family-based genetics: why do people with the same C9ORF72 expansion develop ALS in one case and FTD in another?. Even within the same family, outcomes can diverge.. The leading possibilities include additional genetic factors that modify risk. as well as environmental or lifestyle contributors—though no specific lifestyle trigger has been established.. Researchers also face a striking contrast: some individuals with large C9ORF72 repeat expansions reach old age without developing disease.. Understanding why that subgroup remains healthy could point toward protective pathways that future drugs might mimic.
The new roadmap also changes how scientists organize themselves.. Even though ALS and FTD are now recognized as related, the research and clinical communities have historically operated separately.. A practical next step is to compare DNA patterns between C9ORF72-positive ALS patients and C9ORF72-positive FTD patients. searching for other differences that tilt the balance toward one phenotype or the other.. That kind of side-by-side comparison could identify modifiers that not only explain individual variation but also suggest new targets.
In a field where the hardest problems are often the ones with the most biology packed into a single cell. the C9ORF72 discovery stands out because it connects diagnosis. research design. and therapy strategy.. It also reframes a question many patients and families have asked—whether ALS and FTD are truly separate—into something more testable: they may be different faces of a shared molecular disruption.
And for the scientists pushing this work forward, the message is clear. The next breakthroughs may come not only from finding genes, but from figuring out how that gene’s complex repeat biology drives the specific pathways that ultimately shape what patients experience.